Furthermore, pre-clinical and clinicals studies are needed to evaluate the efficacy and safety of potential interventions, such as inhibiting the transcriptional activation of FOS gene family members or administering lifespan-extending drugs like Deferoxamine and Resveratrol, in reducing accelerated aging in MDD and SUD patients. Here, FOS is linked to major depressive disorder.